Merck Q2 Earnings Preview: Analyst Expectations, Jim Cramer's View, And The Spotlight On Keytruda
EXCLUSIVE: eFFECTOR Therapeutics Announces SPAC Deal To Advance Cancer-Fighting Pipeline
Goldman Sachs Upgrades Merck On Cancer, HIV, COVID-19 Pipeline
Merck Analysts Focus On Fundamentals, Keytruda Strength Following Guidance Cut
Keytruda Recent News
What Drove Merck's Keytruda Shortfall In Q4
What's Behind PDS Biotech's Rally?
Merck's Keytruda Gets A Double Dose Of Positive News
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
Merck's Keytruda Vs. Bristol-Myers Squibb's Opdivo In Q1 And Beyond
Iovance Issues Cancer Trial Updates Ahead Of ASCO Meeting, Sending Stock Skyward
Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates
Bristol-Myers Squibb Withdraws Regulatory Application For Lung Cancer Combo Drug
Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates
Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates
Merck Is Up 40% In 2018: What's Driving The Rally?
Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates
Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates
Merck, Bristol Myers Shares Move On Alleged FDA Alert On Keytruda
Incyte Falls 20% After Cancer Drug Fails Phase 3 Trial
Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates
Early Keytruda Results Win Merck An Upgrade
The Bull Thesis For Merck Is Evaporating
Analyst Grows Cautious On Merck's Keytruda
Boosted By Keytruda, Citi Upgrades Merck To Buy For The First Time Ever
Ahead Of Earnings: Why You Should Be Buying Merck And Selling Bristol-Myers
Tracking The Busy June PDUFA Calendar
The Most Notable Abstracts Released Ahead Of ASCO 2017